{"id":"ad109","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AD109 works by antagonizing adenosine A2A receptors, which are expressed on immune cells and suppress anti-tumor immunity when activated by adenosine in the tumor microenvironment. By blocking this pathway, the drug relieves immune suppression and enhances T cell and natural killer cell function, promoting anti-tumor immune responses. This mechanism is often combined with checkpoint inhibitors to improve overall anti-tumor efficacy.","oneSentence":"AD109 is an adenosine A2A receptor antagonist that blocks inhibitory signaling in the tumor microenvironment to enhance immune cell activation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:59:28.506Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)"}]},"trialDetails":[{"nctId":"NCT05811247","phase":"PHASE3","title":"Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)","status":"COMPLETED","sponsor":"Apnimed","startDate":"2023-08-28","conditions":"OSA","enrollment":660},{"nctId":"NCT05813275","phase":"PHASE3","title":"Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)","status":"COMPLETED","sponsor":"Apnimed","startDate":"2023-09-16","conditions":"OSA","enrollment":646},{"nctId":"NCT06566820","phase":"PHASE3","title":"Continuation Protocol for Obstructive Sleep Apnea (OSA)","status":"ENROLLING_BY_INVITATION","sponsor":"Apnimed","startDate":"2024-07-03","conditions":"OSA","enrollment":1280},{"nctId":"NCT06400615","phase":"PHASE2","title":"Study That Tests AD109 in Patients Taking GLP-1 Drugs","status":"COMPLETED","sponsor":"Apnimed","startDate":"2024-05-20","conditions":"OSA","enrollment":40},{"nctId":"NCT04580394","phase":"PHASE2","title":"Crossover Trial of AD109 in Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"Apnimed","startDate":"2020-10-27","conditions":"Obstructive Sleep Apnea","enrollment":60},{"nctId":"NCT04631107","phase":"PHASE2","title":"AD109 Dose Finding in Mild to Moderate OSA","status":"COMPLETED","sponsor":"Apnimed","startDate":"2020-12-22","conditions":"Obstructive Sleep Apnea","enrollment":32},{"nctId":"NCT05071612","phase":"PHASE2","title":"Parallel Arm Trial of AD109 and AD504 In Patients With OSA","status":"COMPLETED","sponsor":"Apnimed","startDate":"2021-11-29","conditions":"OSA - Obstructive Sleep Apnea","enrollment":294},{"nctId":"NCT05128591","phase":"PHASE1","title":"A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2021-11-09","conditions":"Embolism and Thrombosis","enrollment":38}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AD109","genericName":"AD109","companyName":"Apnimed","companyId":"apnimed","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AD109 is an adenosine A2A receptor antagonist that blocks inhibitory signaling in the tumor microenvironment to enhance immune cell activation. Used for Advanced or metastatic solid tumors (in combination with checkpoint inhibitors).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}